GSK plc (NYSE:GSK) Shares Sold by Cromwell Holdings LLC

Cromwell Holdings LLC cut its stake in GSK plc (NYSE:GSK) by 31.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,905 shares of the pharmaceutical company’s stock after selling 1,358 shares during the quarter. Cromwell Holdings LLC’s holdings in GSK were worth $98,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of GSK. Eastern Bank purchased a new position in shares of GSK during the 3rd quarter worth $26,000. Sunbelt Securities Inc. grew its holdings in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Indiana Trust & Investment Management Co grew its holdings in shares of GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust purchased a new position in shares of GSK during the 4th quarter worth $26,000. Finally, Concord Wealth Partners grew its holdings in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK stock opened at $37.04 on Friday. The business has a 50-day moving average of $34.55 and a 200 day moving average of $37.38. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The stock has a market capitalization of $76.76 billion, a price-to-earnings ratio of 23.29, a price-to-earnings-growth ratio of 1.11 and a beta of 0.64. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, sell-side analysts forecast that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 annualized dividend and a dividend yield of 4.25%. The ex-dividend date is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is presently 98.74%.

Analysts Set New Price Targets

GSK has been the subject of a number of research analyst reports. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Morgan Stanley initiated coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, GSK presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.